Join the Oxymorphone group to help and get support from people like you.
Oxymorphone News
FDA Medwatch Alert: FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks
July 31, 2025 – The U.S. Food and Drug Administration is requiring safety labeling changes to all opioid pain medications to better emphasize and explain the risks associated with their long-term...
FDA Medwatch Alert: Drug Safety Communication: All Opioid Pain Medicines - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use
ISSUE: The FDA is requiring several updates to the prescribing information for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medicines. This includes stating for a...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...
FDA Approves Narcan (naloxone) Nasal Spray to Treat Opioid Overdose
November 18, 2015 – Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can...
FDA Medwatch Alert: Endo Pharmaceuticals Opiate Products by Novartis Consumer Health: Public Health Advisory - Potential Safety Risk
Including the following products: Opana ER (oxymorphone hydrochloride) Extended-Release Tablets CII Opana (oxymorphone hydrochloride) CII Oxymorphone hydrochloride Tablets CII PERCOCET (oxycodone...
Endo Announces FDA Approval of a New Formulation of Opana ER Designed to be Crush-Resistant
CHADDS FORD, Pa., Dec. 12, 2011 /PRNewswire/ – Endo Pharmaceuticals (Nasdaq: ENDP) today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Opana® ER ...